MX2017016438A - Chimeric polypeptide, vaccine against babesiosis, immunization methods, detection methods and kit. - Google Patents
Chimeric polypeptide, vaccine against babesiosis, immunization methods, detection methods and kit.Info
- Publication number
- MX2017016438A MX2017016438A MX2017016438A MX2017016438A MX2017016438A MX 2017016438 A MX2017016438 A MX 2017016438A MX 2017016438 A MX2017016438 A MX 2017016438A MX 2017016438 A MX2017016438 A MX 2017016438A MX 2017016438 A MX2017016438 A MX 2017016438A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- chimeric polypeptide
- vaccine against
- kit
- immunization
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
- A61K39/018—Babesia antigens, e.g. Theileria antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
A chimeric polypeptide containing a fragment of MSA-2c antigen bound to a fragment of RAP-1 antigen bound to a fragment of HSP20 antigen, where the antigens are antigens of a Babesia genus parasite. For example, the chimeric polypeptide may be represented by an amino acid sequence which contains at least 89% identity in relation to SEQ ID N° 1. It shows a composition for a vaccine against babesiosis, immunization methods and detection methods.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ARP150101988A AR100931A1 (en) | 2015-06-22 | 2015-06-22 | CHEMICAL POLIPEPTIDE, VACCINE AGAINST BABESIOSIS, IMMUNIZATION METHODS, DETECTION METHODS AND KIT |
PCT/US2016/038611 WO2016209859A1 (en) | 2015-06-22 | 2016-06-22 | Chimeric polypeptide, vaccine against babesiosis, immunization methods, detection methods and kit |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2017016438A true MX2017016438A (en) | 2018-08-15 |
Family
ID=57585545
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017016438A MX2017016438A (en) | 2015-06-22 | 2016-06-22 | Chimeric polypeptide, vaccine against babesiosis, immunization methods, detection methods and kit. |
Country Status (5)
Country | Link |
---|---|
AR (1) | AR100931A1 (en) |
BR (1) | BR112017027804A2 (en) |
CO (1) | CO2018000255A2 (en) |
MX (1) | MX2017016438A (en) |
WO (1) | WO2016209859A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10760137B2 (en) * | 2017-07-18 | 2020-09-01 | Roche Molecular Systems, Inc. | Compositions and methods for detection of Babesia |
CN113740529B (en) * | 2021-08-25 | 2023-05-26 | 华中农业大学 | Babesia canis antibody latex agglutination detection kit and preparation method and application thereof |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8710009B2 (en) * | 2004-05-26 | 2014-04-29 | The Texas A&M University System | HSP20 inhibits amyloidogenesis and neurotoxicity |
US20130287786A1 (en) * | 2010-12-29 | 2013-10-31 | Theodorus Petrus Maria Schetters | Canine babesiosis vaccine antigen |
-
2015
- 2015-06-22 AR ARP150101988A patent/AR100931A1/en unknown
-
2016
- 2016-06-22 MX MX2017016438A patent/MX2017016438A/en unknown
- 2016-06-22 WO PCT/US2016/038611 patent/WO2016209859A1/en active Application Filing
- 2016-06-22 BR BR112017027804A patent/BR112017027804A2/en active Search and Examination
-
2018
- 2018-01-12 CO CONC2018/0000255A patent/CO2018000255A2/en unknown
Also Published As
Publication number | Publication date |
---|---|
BR112017027804A2 (en) | 2018-08-28 |
WO2016209859A1 (en) | 2016-12-29 |
AR100931A1 (en) | 2016-11-09 |
CO2018000255A2 (en) | 2018-04-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12017501287A1 (en) | A novel complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist | |
MX2017008187A (en) | Combination of listeria-based vaccine with anti-ox40 or anti-gitr antibodies. | |
MX2018011425A (en) | Dna antibody constructs and method of using same. | |
MX2018001213A (en) | Novel methods for inducing an immune response. | |
NZ729519A (en) | Methods and compositions for intra-nasal immunization with recombinant mva encoding flagellin | |
AR110321A1 (en) | ANTITAU ANTIBODIES AND METHODS OF USE | |
WO2015134722A3 (en) | Methods and compositions for increasing a t-effector cell to regulatory t cell ratio | |
MX348071B (en) | Fc variants. | |
WO2013106834A3 (en) | Immunogenic wt-1 peptides and methods of use thereof | |
MX2017000836A (en) | Listeria-based immunogenic compositions for eliciting anti-tumor responses. | |
CY1119916T1 (en) | IMMUNE COMPOSITION | |
WO2014113490A3 (en) | Immunogenic wt-1 peptides and methods of use thereof | |
EP4324481A3 (en) | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same | |
MX2017005642A (en) | Anti-ang2 antibodies and methods of use. | |
MX2016002937A (en) | Oncology vaccine. | |
WO2015107363A3 (en) | Mycobacterial antigen composition | |
BR112012031211A2 (en) | methods and vaccine to reduce campylobacter infection | |
PH12021550521A1 (en) | Antibodies that potently neutralize rabies virus and other lyssaviruses and uses thereof | |
NZ721015A (en) | Mutant fragments of ospa and methods and uses relating thereto | |
BR112017018703A2 (en) | peptide derived from gpc3, pharmaceutical composition for treating or preventing cancer using the same, inducing immunity, and method for producing antigen presenting cells | |
WO2015112558A3 (en) | Peptides, devices, and methods for the detection of anaplasma antibodies | |
MY191217A (en) | Group a streptococcus vaccine | |
EP3103471A3 (en) | Acinetobacter baumanii antigens and the uses thereof | |
WO2018172259A3 (en) | Improved li vaccine adjuvant | |
MX2017016438A (en) | Chimeric polypeptide, vaccine against babesiosis, immunization methods, detection methods and kit. |